Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628882 | 0.89 | MAPK1 (0.45) | PTPN11MAPK1DYRK1AAKT1BTK | |
| Formic Acid SCHEMBL31745015 | 0.76 | DYRK1A (0.49) | DYRK1AAKT1 | |
| SCHEMBL2628883 | 0.73 | CCR1 (0.42) | MAPK1DYRK1AAKT1BTK | |
| SCHEMBL29696445 | 0.70 | BTK (0.52) | MAPK1DYRK1AAKT1BTKAURKA | |
| SCHEMBL19231054 | 0.70 | BTK (0.52) | MAPK1DYRK1AAKT1BTKAURKA | |
| Quinolin-4-Amine SCHEMBL29015439 | 0.68 | NCF1 (0.78) | PTPN11MAPK1NCF1NR4A2SOS2 | |
| SCHEMBL29696528 | 0.68 | KDM5A (0.51) | — | |
| SCHEMBL24348992 | 0.66 | MAPK1 (0.45) | MAPK1DYRK1AAKT1 | |
| SCHEMBL1473269 | 0.66 | DYRK1A (0.53) | MAPK1DYRK1AAKT1NR4A2SOS2 | |
| SCHEMBL1473042 | 0.66 | MAPK1 (0.45) | MAPK1DYRK1AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, SMN1; SMN2, ATXN10 | PTPN11 4671/4885MAPK1 4425/4885DYRK1A 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.